Chemomab Advances PSC Therapy with Positive Phase 2 Data Chemomab reported encouraging 48-week data for its PSC therapy, nebokitug, showing substantial improvements in liver biomarkers and reduced disease progression. The findings bolster the company’s Phase 3 plans, offering hope for a disease-modifying treatment in primary sclerosing cholangitis, a condition lacking FDA-approved options.4